OXR1

Summary

OXR1 (oxidation resistance 1, HGNC:15822) is a protein-coding gene on chromosome 8q23.1, encoding Oxidation resistance protein 1 (Q8N573). May be involved in protection from oxidative damage.

Predicted to enable oxidoreductase activity. Predicted to be involved in response to oxidative stress. Predicted to act upstream of or within several processes, including adult walking behavior; negative regulation of cellular response to oxidative stress; and negative regulation of peptidyl-cysteine S-nitrosylation. Located in mitochondrion. Implicated in cerebellar hyplasia/atrophy, epilepsy, and global developmental delay.

Source: NCBI Gene 55074 — RefSeq curated summary.

At a glance

• Gene–disease (curated): isolated cerebellar hypoplasia/agenesis (Strong, GenCC) — +1 more curated relationship
• Clinical variants (ClinVar): 180 total — 2 pathogenic
• Phenotypes (HPO): 11
• Druggable target: yes
• MANE Select transcript: NM_001198533

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15822
Approved symbol	OXR1
Name	oxidation resistance 1
Location	8q23.1
Locus type	gene with protein product
Status	Approved
Aliases	TLDC3
Ensembl gene	ENSG00000164830
Ensembl biotype	protein_coding
OMIM	605609
Entrez	55074

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 10 protein_coding, 6 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay, 1 retained_intron

ENST00000297447, ENST00000312046, ENST00000435082, ENST00000438229, ENST00000442977, ENST00000449762, ENST00000497705, ENST00000517455, ENST00000517566, ENST00000517686, ENST00000519415, ENST00000521369, ENST00000521592, ENST00000521864, ENST00000521963, ENST00000531443, ENST00000577661, ENST00000658832, ENST00000661818

RefSeq mRNA: 6 — MANE Select: NM_001198533 NM_001198532, NM_001198533, NM_001198534, NM_001198535, NM_018002, NM_181354

CCDS: CCDS47909, CCDS56547, CCDS56548, CCDS56549, CCDS56550, CCDS6304

Canonical transcript exons

ENST00000517566 — 17 exons

Exon	Start	End
ENSE00001087849	106713823	106713985
ENSE00001087855	106710622	106710790
ENSE00001822300	106750806	106752694
ENSE00003479118	106737520	106737600
ENSE00003497307	106739458	106739583
ENSE00003505994	106684246	106684359
ENSE00003516339	106683199	106683306
ENSE00003530747	106692728	106692877
ENSE00003601519	106702906	106703090
ENSE00003615809	106745789	106745862
ENSE00003661621	106742222	106742317
ENSE00003675755	106740343	106740495
ENSE00003713479	106359476	106359636
ENSE00003726003	106706382	106707145
ENSE00003730546	106679210	106679292
ENSE00003751246	106518943	106519139
ENSE00003913757	106270190	106270367

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 99.00.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 42.8757 / max 1021.5665, expressed in 1817 samples.

FANTOM5 promoters (21 alternative TSS)

Promoter ID	TPM avg	Samples expressed
90239	16.6859	1767
90216	16.6550	1444
90243	5.4522	1323
90223	1.0630	117
90241	0.5267	181
90215	0.4402	131
90218	0.3875	196
90242	0.3218	144
90240	0.2884	129
90217	0.2639	114

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pons	UBERON:0000988	99.00	gold quality
calcaneal tendon	UBERON:0003701	97.92	gold quality
lateral nuclear group of thalamus	UBERON:0002736	97.90	gold quality
trigeminal ganglion	UBERON:0001675	97.85	gold quality
sperm	CL:0000019	97.82	gold quality
adrenal tissue	UBERON:0018303	97.79	gold quality
dorsal root ganglion	UBERON:0000044	97.55	gold quality
seminal vesicle	UBERON:0000998	97.15	gold quality
Brodmann (1909) area 23	UBERON:0013554	97.12	gold quality
corpus epididymis	UBERON:0004359	97.00	gold quality
prefrontal cortex	UBERON:0000451	96.75	gold quality
colonic epithelium	UBERON:0000397	96.49	gold quality
superior vestibular nucleus	UBERON:0007227	96.04	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	95.90	gold quality
superior frontal gyrus	UBERON:0002661	95.83	gold quality
frontal cortex	UBERON:0001870	95.81	gold quality
right adrenal gland cortex	UBERON:0035827	95.75	gold quality
right adrenal gland	UBERON:0001233	95.73	gold quality
parietal lobe	UBERON:0001872	95.52	gold quality
postcentral gyrus	UBERON:0002581	95.49	gold quality
caput epididymis	UBERON:0004358	95.44	gold quality
Brodmann (1909) area 9	UBERON:0013540	95.42	gold quality
neocortex	UBERON:0001950	95.34	gold quality
adrenal gland	UBERON:0002369	95.10	gold quality
left adrenal gland	UBERON:0001234	95.01	gold quality
adrenal cortex	UBERON:0001235	94.97	gold quality
tibia	UBERON:0000979	94.87	gold quality
occipital lobe	UBERON:0002021	94.73	gold quality
cerebral cortex	UBERON:0000956	94.72	gold quality
substantia nigra pars compacta	UBERON:0001965	94.69	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-MTAB-9154	yes	780.11
E-HCAD-35	yes	77.51
E-CURD-119	yes	42.41
E-CURD-112	yes	15.53
E-MTAB-7316	no	33.71
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

167 targeting OXR1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-656-3P	100.00	72.15	2788
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-12121	99.99	66.64	255
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-4715-3P	99.98	66.03	670
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-3912-5P	99.95	66.11	925

Literature-anchored findings (GeneRIF, showing 16)

• Data show that human and yeast oxidation resistance 1 (OXR1) genes are induced by heat and oxidative stress and that their proteins localize to the mitochondria and function to protect against oxidative damage. (PMID:15060142)
• human OXR1 is capable of reducing the DNA damaging effects of reactive oxygen species when expressed in bacteria, indicating the protein has an activity that can contribute to oxidation resistance. (PMID:17391516)
• The protein segment encoded by exon 8 plays an important role in the anti-oxidative function of the human OXR1 protein. (PMID:22873401)
• OXR1 upregulates the expression of antioxidant genes via the p21 signaling pathway to suppress hydrogen peroxide-induced oxidative stress and maintain mtDNA integrity. (PMID:25236744)
• Oxr1 serves as a potential therapeutic target for ALS and other neurodegenerative disorders characterized by TDP-43 or FUS pathology. (PMID:25792726)
• OXR1 may act as a sensor of cellular oxidative stress to regulate the transcriptional networks required to detoxify reactive oxygen species and modulate cell cycle and apoptosis. (PMID:26616534)
• findings provide new insights into the mechanism by which senescent cells are highly resistant to oxidative stress and suggest that OXR1 is a novel senolytic target that can be further exploited for the development of new senolytic agents (PMID:29766639)
• The results of the present study indicated that sevoflurane exerts its neurotoxic effect by regulating the hsamiR302e/OXR1 axis. Therefore, the manipulation of the hsamiR302e/OXR1 pathway will be useful for preventing sevofluraneinduced neurotoxicity. (PMID:30221705)
• Low OXR1 expression is associated with the development of esophageal squamous cell carcinoma. (PMID:30852977)
• MiR-616 promotes the progression of pancreatic carcinoma by targeting OXR1. (PMID:31502810)
• Over-expression of Oxr1 was able to delay neuromuscular abnormalities in the hSOD1G93A amyotrophic lateral sclerosis mouse model. (PMID:31642482)
• Loss of OXR1 is Associated with an Autosomal-Recessive Neurological Disease with Cerebellar Atrophy and Lysosomal Dysfunction. (PMID:31785787)
• Oxidation resistance 1 prevents genome instability through maintenance of G2/M arrest in gamma-ray-irradiated cells. (PMID:31845986)
• A novel recessive mutation in OXR1 is identified in patient with hearing loss recapitulated by the knockdown zebrafish. (PMID:36130215)
• A loss-of-function mutation in human Oxidation Resistance 1 disrupts the spatial-temporal regulation of histone arginine methylation in neurodevelopment. (PMID:37773136)
• OXR1 maintains the retromer to delay brain aging under dietary restriction. (PMID:38212606)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	oxr1b	ENSDARG00000063310
mus_musculus	Oxr1	ENSMUSG00000022307
rattus_norvegicus	Oxr1	ENSRNOG00000056487

Paralogs (3): TLDC2 (ENSG00000101342), NCOA7 (ENSG00000111912), MEAK7 (ENSG00000140950)

Protein

Protein identifiers

Oxidation resistance protein 1 — Q8N573 (reviewed: Q8N573)

All UniProt accessions (6): C9JY63, E5RFD1, E5RII8, E9PLW2, H0YC07, Q8N573

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in protection from oxidative damage.

Subcellular location. Mitochondrion.

Disease relevance. Cerebellar hypoplasia/atrophy, epilepsy, and global developmental delay (CHEGDD) [MIM:213000] An autosomal recessive neurodevelopmental disorder characterized by infantile onset of hypotonia, global developmental delay, delayed walking, and severely impaired intellectual development with profound speech delay. Patients manifest cerebellar atrophy and childhood-onset epilepsy. The disease is caused by variants affecting the gene represented in this entry.

Induction. By heat shock and oxidative stress.

Similarity. Belongs to the OXR1 family.

Isoforms (8)

UniProt ID	Names	Canonical?
Q8N573-1	1	yes
Q8N573-2	2
Q8N573-3	3
Q8N573-4	4
Q8N573-5	5
Q8N573-6	6
Q8N573-7	7
Q8N573-8	8

RefSeq proteins (6): NP_001185461, NP_001185462, NP_001185463, NP_001185464, NP_060472, NP_851999 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006571	TLDc_dom	Domain
IPR018392	LysM	Domain
IPR036779	LysM_dom_sf	Homologous_superfamily

Pfam: PF01476, PF07534

UniProt features (48 total): splice variant 13, modified residue 11, compositionally biased region 6, region of interest 5, sequence conflict 5, sequence variant 4, domain 3, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8N573-F1	60.31	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (11): 91, 119, 201, 202, 204, 294, 334, 336, 341, 346, 496

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 290 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, WENDT_COHESIN_TARGETS_UP, TGGTGCT_MIR29A_MIR29B_MIR29C, GOBP_NEGATIVE_REGULATION_OF_NEURON_APOPTOTIC_PROCESS, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, AAGCAAT_MIR137, GOBP_BEHAVIOR, GCANCTGNY_MYOD_Q6, GOBP_ADULT_BEHAVIOR, GOBP_NEGATIVE_REGULATION_OF_RESPONSE_TO_OXIDATIVE_STRESS, GOBP_ADULT_LOCOMOTORY_BEHAVIOR, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, MODULE_503, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, ONKEN_UVEAL_MELANOMA_UP

GO Biological Process (6): response to oxidative stress (GO:0006979), adult walking behavior (GO:0007628), negative regulation of neuron apoptotic process (GO:0043524), neuron apoptotic process (GO:0051402), cellular response to hydroperoxide (GO:0071447), negative regulation of cellular response to oxidative stress (GO:1900408)

GO Molecular Function (2): oxidoreductase activity (GO:0016491), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), nucleolus (GO:0005730), mitochondrion (GO:0005739)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular response to oxidative stress	2
intracellular membrane-bounded organelle	2
response to stress	1
adult locomotory behavior	1
walking behavior	1
negative regulation of apoptotic process	1
regulation of neuron apoptotic process	1
neuron apoptotic process	1
apoptotic process	1
response to hydroperoxide	1
cellular response to oxygen-containing compound	1
negative regulation of cellular process	1
regulation of cellular response to oxidative stress	1
negative regulation of response to oxidative stress	1
catalytic activity	1
binding	1
nuclear lumen	1
intracellular membraneless organelle	1
cytoplasm	1

Protein interactions and networks

STRING

932 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OXR1	HCRT	O43612	926
OXR1	HCRTR1	O43613	793
OXR1	HCRTR2	O43614	693
OXR1	OR13H1	Q8NG92	507
OXR1	ATP6V1B1	P15313	499
OXR1	FOS	P01100	472
OXR1	PRMT5	O14744	454
OXR1	PRMT1	Q99873	450
OXR1	PRDX2	P31945	443
OXR1	TMEM150A	Q86TG1	434
OXR1	KEAP1	Q14145	433
OXR1	CDC16	Q13042	403
OXR1	DMXL1	Q9Y485	403
OXR1	GPX7	Q96SL4	384
OXR1	OXSR1	O95747	366

IntAct

7 interactions, top by confidence:

A	B	Type	Score
OXR1	RFC1	psi-mi:“MI:0915”(physical association)	0.400
OXR1		psi-mi:“MI:0915”(physical association)	0.370
hspa1a_hspa1b_human-1	SHTN1	psi-mi:“MI:0914”(association)	0.350
		psi-mi:“MI:0914”(association)	0.350
CLIC6	OXR1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (57): OXR1 (Two-hybrid), OXR1 (Affinity Capture-MS), OXR1 (Affinity Capture-MS), OXR1 (Affinity Capture-MS), OXR1 (Affinity Capture-MS), OXR1 (Synthetic Lethality), OXR1 (Proximity Label-MS), OXR1 (Proximity Label-MS), OXR1 (Proximity Label-MS), OXR1 (Proximity Label-MS), OXR1 (Proximity Label-MS), OXR1 (Proximity Label-MS), OXR1 (Proximity Label-MS), OXR1 (Proximity Label-MS), OXR1 (Proximity Label-MS)

ESM2 similar proteins: A0A0R4IBK5, A0JP43, A1A5R8, A2VCV0, B8QB46, P62283, P62285, P62286, P62287, P62288, P62289, P62290, P62291, P62292, P62293, P62294, P62296, P62297, Q06190, Q08AX9, Q12830, Q2T9I9, Q4KLH3, Q4VA55, Q5RA75, Q5TC84, Q5ZMS4, Q65Z40, Q66H73, Q68FF0, Q6DFV7, Q6NSI8, Q6PG04, Q6PUR7, Q6TXG9, Q7T3T8, Q7Z5K2, Q8CJ27, Q8IZT6, Q8K4P8

Diamond homologs: A0PJX2, A2ACG1, A5PKL1, A8KBE0, B4F6Q9, O14284, Q08952, Q0IID2, Q1LWV7, Q3UUG6, Q4KMM3, Q4V8B0, Q5ZJX5, Q5ZMS4, Q6C443, Q6CMK8, Q6DDZ9, Q6DFV7, Q6FSN5, Q6P9B6, Q755A3, Q874Z5, Q8K0P3, Q8N573, Q8NI08, Q9ULP9, Q9VIH7, Q5AEM5, P0CP42, P0CP43, Q6ZZF5, Q7S4P1, Q4I8S2, Q4WX99, Q5B8X6, A1A5K6, Q29RJ2, Q6BJM5, Q08CX5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

180 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	120
Likely benign	21
Benign	2

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
694396	NM_001198533.2(OXR1):c.1100C>G (p.Ser367Ter)	Pathogenic
694397	NM_001198533.2(OXR1):c.2163+1G>T	Pathogenic

SpliceAI

3143 predictions. Top by Δscore:

Variant	Effect	Δscore
8:106676154:ATTT:A	acceptor_gain	1.0000
8:106679205:CCCAG:C	acceptor_loss	1.0000
8:106679206:CCA:C	acceptor_loss	1.0000
8:106679207:CA:C	acceptor_loss	1.0000
8:106679208:A:AG	acceptor_gain	1.0000
8:106679209:G:GA	acceptor_gain	1.0000
8:106679209:GA:G	acceptor_gain	1.0000
8:106679209:GAC:G	acceptor_gain	1.0000
8:106679209:GACA:G	acceptor_gain	1.0000
8:106679209:GACAC:G	acceptor_gain	1.0000
8:106679282:T:TG	donor_gain	1.0000
8:106679291:CT:C	donor_gain	1.0000
8:106679292:TGTAA:T	donor_loss	1.0000
8:106679293:G:A	donor_loss	1.0000
8:106679293:G:GG	donor_gain	1.0000
8:106679294:T:TC	donor_loss	1.0000
8:106683196:CA:C	acceptor_loss	1.0000
8:106683272:A:AG	donor_gain	1.0000
8:106684233:T:TA	acceptor_gain	1.0000
8:106684242:A:AG	acceptor_gain	1.0000
8:106684242:ACAG:A	acceptor_gain	1.0000
8:106684243:C:G	acceptor_gain	1.0000
8:106684243:CA:C	acceptor_loss	1.0000
8:106684244:A:AG	acceptor_gain	1.0000
8:106684244:A:AT	acceptor_loss	1.0000
8:106684244:AG:A	acceptor_gain	1.0000
8:106684245:G:GT	acceptor_gain	1.0000
8:106684245:GG:G	acceptor_gain	1.0000
8:106684245:GGT:G	acceptor_gain	1.0000
8:106684245:GGTT:G	acceptor_gain	1.0000

AlphaMissense

5768 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:106683230:C:A	A113D	1.000
8:106683260:T:C	L123P	1.000
8:106684256:T:A	V142D	1.000
8:106692839:T:C	F214L	1.000
8:106692841:T:A	F214L	1.000
8:106692841:T:G	F214L	1.000
8:106702925:T:C	L233P	1.000
8:106702928:T:C	L234P	1.000
8:106710772:T:C	F593S	1.000
8:106740382:T:A	W736R	1.000
8:106740382:T:C	W736R	1.000
8:106740467:T:C	L764P	1.000
8:106742229:G:A	G776D	1.000
8:106745798:T:A	W809R	1.000
8:106745798:T:C	W809R	1.000
8:106750822:T:A	W836R	1.000
8:106750822:T:C	W836R	1.000
8:106750826:T:C	L837P	1.000
8:106750847:G:A	G844E	1.000
8:106750927:T:A	W871R	1.000
8:106750927:T:C	W871R	1.000
8:106683200:T:A	V103D	0.999
8:106683260:T:A	L123H	0.999
8:106683260:T:G	L123R	0.999
8:106683273:T:A	N127K	0.999
8:106683273:T:G	N127K	0.999
8:106683293:T:A	V134D	0.999
8:106684250:T:C	L140P	0.999
8:106692840:T:C	F214S	0.999
8:106692840:T:G	F214C	0.999

dbSNP variants (sampled 300 via entrez): RS1000008391 (8:106673282 T>C,G), RS1000014291 (8:106674117 CT>C), RS1000017464 (8:106581426 A>G), RS1000022249 (8:106488888 T>G), RS1000024106 (8:106516296 T>G), RS1000026267 (8:106399544 T>C), RS1000028896 (8:106358271 C>A,T), RS1000035126 (8:106406108 G>A), RS1000042376 (8:106698670 C>G), RS1000045678 (8:106411414 G>T), RS1000048279 (8:106439678 A>G,T), RS1000048636 (8:106636433 T>C), RS1000049684 (8:106544071 A>G), RS1000055112 (8:106715138 T>A), RS1000080095 (8:106674907 A>G,T)

Disease associations

OMIM: gene MIM:605609 | disease phenotypes: MIM:213000

GenCC curated gene-disease

Disease	Classification	Inheritance
isolated cerebellar hypoplasia/agenesis	Strong	Autosomal recessive
sensorineural hearing loss disorder	Strong	Autosomal recessive

Mondo (3): isolated cerebellar hypoplasia/agenesis (MONDO:0008939), hearing loss disorder (MONDO:0005365), sensorineural hearing loss disorder (MONDO:0020678)

Orphanet (2): Isolated cerebellar agenesis (Orphanet:1398), Cerebellar hypoplasia-tapetoretinal degeneration syndrome (Orphanet:2246)

HPO phenotypes

11 total (11 of 11 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000639	Nystagmus
HP:0000750	Delayed speech and language development
HP:0001249	Intellectual disability
HP:0001250	Seizure
HP:0001251	Ataxia
HP:0001252	Hypotonia
HP:0001263	Global developmental delay
HP:0001321	Cerebellar hypoplasia
HP:0001337	Tremor
HP:0002650	Scoliosis

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D034381	Hearing Loss	C09.218.458.341; C10.597.751.418.341; C23.888.592.763.393.341
C562568	Cerebellar Hypoplasia (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295901 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

58 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, decreases methylation, increases expression	3
Acetaminophen	increases expression	2
Benzo(a)pyrene	affects methylation	2
Aflatoxin B1	decreases methylation, increases methylation	2
Palmitic Acid	affects cotreatment, increases expression, decreases phosphorylation	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
FR900359	affects phosphorylation	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases expression	1
cobaltous chloride	increases expression	1
zinc chromate	increases abundance, increases expression	1
benzo(e)pyrene	increases methylation	1
1-nitropyrene	increases expression	1
cadmium sulfide	increases expression	1
vanadium pentoxide	decreases expression	1
chromium hexavalent ion	increases abundance, increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
cylindrospermopsin	increases expression	1
CGP 52608	affects binding, increases reaction	1
nutlin 3	affects cotreatment, increases expression	1
ICG 001	increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
bisphenol S	increases methylation	1
jinfukang	affects cotreatment, decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Aerosols	decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4233057	Binding	Induction of OXR1 degradation in ionizing radiation induced human WI38 senescent cells at 5 uM after 24 hrs by Western blot analysis	Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation. — Bioorg Med Chem

Clinical trials (associated diseases)

384 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00205881	PHASE4	COMPLETED	Bilateral Benefit in Adult Users of the HiRes 90K Bionic Ear System
NCT00331539	PHASE4	UNKNOWN	Relationship Between Auto NRT and Behavioural T & C Levels With the Nucleus Freedom Cochlear Implant
NCT00424307	PHASE4	UNKNOWN	Bilateral Cochlear Implant Benefit in Young Children
NCT00765635	PHASE4	COMPLETED	Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal
NCT03321006	PHASE4	COMPLETED	Treating Hearing Loss to Improve Mood and Cognition in Older Adults
NCT01655212	PHASE3	TERMINATED	Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
NCT02005822	PHASE3	COMPLETED	Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
NCT03374514	PHASE3	UNKNOWN	Cochlear Electrical Impedance and the Effect of Topical Dexamethasone on Cochlear Implant Surgery
NCT01499901	PHASE3	WITHDRAWN	Comparison of the Bilateral Sequential and Simultaneous Cochlear Implantation in the Deaf Children
NCT02561091	PHASE3	COMPLETED	AM-111 in the Treatment of Acute Inner Ear Hearing Loss
NCT03331627	PHASE3	COMPLETED	Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL
NCT05532657	PHASE3	ACTIVE_NOT_RECRUITING	ACHIEVE Brain Health Follow-Up Study
NCT02497690	PHASE2	COMPLETED	Effectiveness of Therapy Via Telemedicine Following Cochlear Implants
NCT03107871	PHASE2	ACTIVE_NOT_RECRUITING	Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants
NCT04120116	PHASE2	COMPLETED	FX-322 in Adults With Stable Sensorineural Hearing Loss
NCT05061758	PHASE2	WITHDRAWN	A Trial of LY3056480 in Patients With SNLH
NCT07364747	PHASE2	RECRUITING	Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial
NCT00013455	PHASE2	COMPLETED	Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting
NCT00323427	PHASE2	COMPLETED	Clinical Trial of the Living Well With Hearing Loss Workshop
NCT00552786	PHASE2	COMPLETED	Antioxidation Medication for Noise-induced Hearing Loss
NCT00802425	PHASE2	COMPLETED	Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss
NCT01139281	PHASE2	COMPLETED	The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans
NCT01451853	PHASE2	UNKNOWN	SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
NCT01588925	PHASE2	COMPLETED	Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation
NCT01773278	PHASE2	RECRUITING	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
NCT02832128	PHASE2	COMPLETED	Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)
NCT04915183	PHASE2	RECRUITING	Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
NCT05258773	PHASE2	COMPLETED	Evaluation of the Presence of SENS-401 in the Perilymph
NCT06340633	PHASE2	RECRUITING	SPI-1005 in Adults Receiving Cochlear Implant
NCT02259595	PHASE1	COMPLETED	Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
NCT00582946	PHASE1	COMPLETED	Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding
NCT00584155	PHASE1	WITHDRAWN	Protection From Cisplatin Ototoxicity by Lactated Ringers
NCT01206829	PHASE1	UNKNOWN	Hearing Impairment, Cognitive Therapy and Coping
NCT01256229	PHASE1	COMPLETED	Outcomes In Children With Developmental Delay And Deafness
NCT01343394	PHASE1	WITHDRAWN	Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children
NCT01452607	PHASE1	COMPLETED	Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
NCT04041440	PHASE1	COMPLETED	Speech Recognition Training in Children With Hearing Loss
NCT07218913	PHASE1	RECRUITING	Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
NCT02693704	PHASE2/PHASE3	COMPLETED	Evaluation of a Binaural Spatialization Method for Hearing Aids
NCT02882477	PHASE2/PHASE3	UNKNOWN	Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy